1.41 USD
+0.02 (+1.44%)
Taking everything into account, SSKN scores 1 out of 10 in our fundamental rating. SSKN was compared to 188 industry peers in the Health Care Equipment & Supplies industry. SSKN has a bad profitability rating. Also its financial health evaluation is rather negative. SSKN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SSKN had negative earnings in the past year.
SSKN had a negative operating cash flow in the past year.
In the past 5 years SSKN always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: SSKN reported negative operating cash flow in multiple years.
1.2 Ratios
SSKN has a worse Return On Assets (-37.56%) than 61.17% of its industry peers.
SSKN has a Return On Equity of -3746.75%. This is amonst the worse of the industry: SSKN underperforms 88.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.56% | ||
| ROE | -3746.75% | ||
| ROIC | N/A |
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 57.89%, SSKN perfoms like the industry average, outperforming 56.38% of the companies in the same industry.
SSKN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SSKN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.89% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
2. Health
2.1 Basic Checks
SSKN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SSKN has more shares outstanding
SSKN has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, SSKN has a worse debt to assets ratio.
2.2 Solvency
SSKN has an Altman-Z score of -10.98. This is a bad value and indicates that SSKN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.98, SSKN is doing worse than 79.26% of the companies in the same industry.
A Debt/Equity ratio of 49.58 is on the high side and indicates that SSKN has dependencies on debt financing.
SSKN's Debt to Equity ratio of 49.58 is on the low side compared to the rest of the industry. SSKN is outperformed by 88.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 49.58 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.98 |
ROIC/WACCN/A
WACC10.23%
2.3 Liquidity
A Current Ratio of 0.98 indicates that SSKN may have some problems paying its short term obligations.
SSKN has a worse Current ratio (0.98) than 88.83% of its industry peers.
SSKN has a Quick Ratio of 0.98. This is a bad value and indicates that SSKN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.75, SSKN is doing worse than 86.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.75 |
3. Growth
3.1 Past
SSKN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.38%.
The Revenue has been growing slightly by 0.61% in the past year.
The Revenue has been growing slightly by 1.22% on average over the past years.
EPS 1Y (TTM)-0.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.08%
Revenue 1Y (TTM)0.61%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-21.23%
3.2 Future
Based on estimates for the next years, SSKN will show a very strong growth in Earnings Per Share. The EPS will grow by 28.30% on average per year.
SSKN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.83% yearly.
EPS Next Y37.76%
EPS Next 2Y28.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-1.34%
Revenue Next 2Y4.04%
Revenue Next 3Y1.83%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
SSKN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SSKN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SSKN's earnings are expected to grow with 28.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.3%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for SSKN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SSKN (12/3/2025, 4:30:00 PM)
1.41
+0.02 (+1.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners29.88%
Inst Owner Change-4.6%
Ins Owners3.09%
Ins Owner Change-0.24%
Market Cap8.30M
Revenue(TTM)33.56M
Net Income(TTM)-11.54M
Analysts85
Price Target8.16 (478.72%)
Short Float %7.03%
Short Ratio0.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-57.4%
Min EPS beat(2)-104.6%
Max EPS beat(2)-10.2%
EPS beat(4)0
Avg EPS beat(4)-101.01%
Min EPS beat(4)-271.14%
Max EPS beat(4)-10.2%
EPS beat(8)2
Avg EPS beat(8)-96.62%
EPS beat(12)4
Avg EPS beat(12)-54.24%
EPS beat(16)7
Avg EPS beat(16)-36.31%
Revenue beat(2)0
Avg Revenue beat(2)-10.27%
Min Revenue beat(2)-12.25%
Max Revenue beat(2)-8.28%
Revenue beat(4)2
Avg Revenue beat(4)-3.72%
Min Revenue beat(4)-12.25%
Max Revenue beat(4)4.61%
Revenue beat(8)3
Avg Revenue beat(8)-5.92%
Revenue beat(12)5
Avg Revenue beat(12)-3.01%
Revenue beat(16)7
Avg Revenue beat(16)-1.73%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.25 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 26.96 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.67
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS5.58
BVpS0.05
TBVpS-1.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.56% | ||
| ROE | -3746.75% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.89% | ||
| FCFM | N/A |
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
F-Score3
Asset Turnover1.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 49.58 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 14.87% | ||
| Cap/Sales | 2.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.75 | ||
| Altman-Z | -10.98 |
F-Score3
WACC10.23%
ROIC/WACCN/A
Cap/Depr(3y)63.47%
Cap/Depr(5y)69.64%
Cap/Sales(3y)9.91%
Cap/Sales(5y)10.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.08%
EPS Next Y37.76%
EPS Next 2Y28.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.61%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-21.23%
Revenue Next Year-1.34%
Revenue Next 2Y4.04%
Revenue Next 3Y1.83%
Revenue Next 5YN/A
EBIT growth 1Y-21.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year114.9%
EBIT Next 3Y114.72%
EBIT Next 5YN/A
FCF growth 1Y54.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.81%
OCF growth 3Y-50.07%
OCF growth 5Y-39.02%
STRATA SKIN SCIENCES INC / SSKN FAQ
What is the fundamental rating for SSKN stock?
ChartMill assigns a fundamental rating of 1 / 10 to SSKN.
Can you provide the valuation status for STRATA SKIN SCIENCES INC?
ChartMill assigns a valuation rating of 1 / 10 to STRATA SKIN SCIENCES INC (SSKN). This can be considered as Overvalued.
How profitable is STRATA SKIN SCIENCES INC (SSKN) stock?
STRATA SKIN SCIENCES INC (SSKN) has a profitability rating of 1 / 10.